Notable Mover Report On Dec 14, 2017 – Global Blood Therapeutics
- Shares show some rebounding after having tumbled for the past few days due to the ASH-data released.
- Compassionate case study outcomes were highly encouraging. And yet, two unrelated deaths from very sick patients caused the stock to crash.
- This is a truncated version of the in-depth Integrated BioSci Report that was published in advanced to subscribers.
On Dec. 14, 2017, the shares of Global Blood Therapeutics (NASDAQ:GBT), a firm focusing on the innovation and commercialization of medicine to treat serious blood disorders, traded up by $1.15 at $39.50 (for 3% profits) as of 2:56 pm ET. Prior to this slight rebound, the stock tumbled for three consecutive days – started on Monday when the company announced reported the clinical data of lead drug, voxelotor (at the 59th annual meeting of the American Society of Hematology (“ASH”): the event was held at the Georgia World Congress Center in Atlanta. Despite the recent depreciation, Integrated BioSci Investing subscribers still benefited over 20% on the stock (since it was recommended by our expert guest in the Integrated BioSci Interview series). In this report, we’ll go over the data results as well as to address the two unrelated deaths (and to provide further insight into the firm).
Based in South San Francisco, CA, Global Blood Therapeutics (“GBT”) is developing a stellar molecule voxelotor to treat the dreaded blood disorder, sickle cell disease (“SCD”). Due to a single base pair genetic mutation, SCD is a hemoglobinopathy that causes red blood cells to form a sickle shape – in the oxygen deprivation states. Consequently, patients suffer from the repetitive extremely painful vaso-occlusive crises (“VOCs”) that, in and of itself, are managed with opioid pain medications. As the developmental drug in its own class (an -elotor), the oxygen affinity modulator, voxelotor, is most likely to fill the strong demand for better therapeutics options. The said drug is currently being investigated in its phase 3 trial coined HOPE with the estimated completion date on June 29, 2019. There is also another study (HOPE-KIDS1) seeking to evaluate the safety and efficacy and pharmacokinetics (“PK”) in the pediatric groups (age 6-17 years old).